Stem Cell Banking
Government entities, academic institutions, biotech firms, and pharmaceutical companies all build banks of iPS cells that represent a wide range of individual genotypes and phenotypes. Through its MyCell® Products, CDI is uniquely positioned to deliver access to relevant iPS cell-derived biological models by leveraging these capabilities:
- High-throughput manufacturing environment
- Rigorous quality control and information management systems
- Strong intellectual property portfolio
- Solid business infrastructure
CDI is actively engaged in a number of large-scale induced pluripotent stem (iPS) cell reprogramming and banking projects with the goal of creating broadly available resources of iPS cells that represent typical human diversity, various disease states, and adverse drug reactions. Most notably, CDI has been awarded a $16 million grant by the California Institute for Regenerative Medicine (CIRM) to derive three iPS cell lines from each of 3,000 donors representing Alzheimer’s disease, autism spectrum disorders, cerebral palsy, epilepsy, familial dilated cardiomyopathy, age-related macular degeneration,
viral hepatitis, non-alcoholic steatohepatitis, and idiopathic pulmonary fibrosis.
The CIRM project follows a $6.3 million grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) to CDI and the Medical College of Wisconsin (MCW) to investigate the mechanisms underlying left ventricular hypertrophy. CDI’s role in this project is to generate iPS cell lines and cardiomyocytes from 250 Caucasian and African-American donors selected from the Hypertension Genetic Epidemiology Network (HyperGEN). The MCW will then employ the iPS cell-derived cardiomyocytes in studies to elucidate the genetic mechanisms underlying the disease.